Repeat surgical aortic valve replacement (Redo-SAVR) is the gold standard for the treatment of degenerated aortic BP valves, but it is burdened with significant surgical risk, especially in those patients with patent coronary artery grafts.

2018年7月2日 · 面对这个问题，目前的标准治疗是行 redo-surgical valve replacement（redo-SAVR）手术，但是再次行 SAVR 会大大增加患者术后死亡率和并发症发生风险。 好消息是，TAVR 的发展为我们带来的瓣中瓣技术（Transcatheter Valve-in-Valve Implantation，ViV-TAVR），或许可以为这些患者带来 ...

Background: Clinical outcomes of redo surgical aortic valve replacement (redo-SAVR) compared with valve-in-valve transcatheter aortic valve replacement (VIV-TAVR) are poorly understood. This study compared short- and midterm outcomes of patients undergoing isolated redo-SAVR vs VIV-TAVR after previous SAVR.

2023年1月14日 · 对于外科瓣膜衰败患者，相比于再次行外科主动脉瓣置换术（SAVR），瓣中瓣TAVR（ViV TAVR）治疗带来的创伤更小、安全性更高，已成为无法接受再次SAVR（Redo-SAVR）治疗或高危患者的有效替代治疗方式。 对于TAVR治疗后瓣膜衰败的患者，部分研究报道了再次TAVR治疗（Redo-TAVR）的良好结果，但也有研究指出部分患者因无法接受Redo-TAVR而行外科开胸取出介入瓣膜（TAVR Explantation）所带来的不良结局。 充分了解每一种情况的 …

2023年8月30日 · ViV TAVR组对心力衰竭再入院的竞争风险累积发病率估计明显更高，这一发现是基于仅在ViV组少数患者中可获得的数据（ViV，5.30% vs redo-SAVR，89.18%）。 研究人员在《J Thorac Cardiovasc Surg》上报道，瓣中瓣经导管主动脉瓣置换术（ViV TAVR）和再次外科主动脉瓣置换术（redo-SAVR）的死亡率相当。 试验方法. 这项观察性回顾性研究使用机构数据库比较redo-SAVR 与 ViV TAVR后的术后并发症、经瓣膜梯度、死亡率和心力衰竭再入院率。 参与者 …

2025年1月24日 · Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) is associated with improved perioperative safety compared with redo surgical aortic valve replacement (redo-SAVR), but long-term outcomes remain uncertain.

2023年1月9日 · Valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) has emerged as a useful alternative intervention to redo-surgical aortic valve replacement (Redo-SVAR) for the treatment of degenerated bioprosthesis valve.

2021年1月21日 · In this large systematic review and meta-analysis including 12 comparative studies of ViV TAVR and redo SAVR, we demonstrate that ViV TAVR was associated with lower rates of 30-day mortality (overall and for matched populations), and major bleeding, as well as with shorter hospital stay.

2024年11月26日 · This study compared outcomes between patients undergoing valve-in-valve transcatheter aortic valve replacement (ViV TAVR) and redo surgical aortic valve replacement (redo SAVR) using a retrospective analysis of institutional databases, which included data from 2013 to 2022 for TAVR and 2011 to 2022 for SAVR.

2023年4月24日 · The number of post-TAVR reoperations is increasing and represent a high-risk population. Yet even in isolated SAVR cases, SAVR after TAVR is independently associated with increased risk of mortality. Patients with life expectancy beyond a TAVR valve and unsuitable anatomy for redo-TAVR should consid …